Arndt Vogel

Arndt Vogel at Hannover Medical School is a leading European expert in hepatobiliary oncology who has contributed to HER2 targeting in biliary tract cancer including the HERB trial. His research has characterized the prevalence and clinical significance of HER2 amplification and mutation across different BTC subtypes. He has been a key contributor to ESMO guidelines for biliary tract cancer management and has led multiple European BTC clinical trials. His work on identifying and exploiting actionable alterations beyond FGFR2 and IDH1 has broadened precision oncology options for BTC patients.